close

Enter

Log in using OpenID

Adult Vaccines Market Set Explosive Growth to 2026

embed
The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 - 2025). Vaccination and immunization is aids in prevention of diseases among adults and chi
Adult Vaccines Market Is Forecasted To Witness A
Thriving Growth By 2026
Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis,
Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella,
Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and
Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or
Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate
Vaccines), and by Region - Global Industry Insights, and Forecast till 2025
The Global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to
witness a robust CAGR of 7.1% over the forecast period (2017 - 2025).
Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are
biological suspensions that contain an agent that resembles the disease causing microorganisms and are
often made from inactivated microbes, toxins or surface proteins. The active agents present in the
vaccine stimulates body’s immune system to recognize the disease causing agent as 'foreign substance'
and develop antibodies against it. Vaccines are a preferable and highly recommended preventive
measure against certain severe diseases, however, have mild side effects.
Market Dynamics
Development of vaccines for various new diseases and rising awareness regarding advantages of
preventive medication are the two prominent factors supporting growth of the market. For instance,
according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around
1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated
hospitalizations, representing 6.5% lowering of disease burden.
Among the middle-income and emerging economies, relevant Indian government funding agencies
such as Department of Biotechnology (DBT) and The Indian Council of Medical Research (ICMR) are
scaling up their investments in research and development associated to vaccine development. For
instance, in 2015, the Department of Biotechnology projected a funding of US$ 2.95 million for
Malaria Vaccine Initiative, to develop vaccine against Plasmodium falciparum and P. vivax.
On the other hand, growing awareness among the populace regarding prevention of diseases facilitated
by vaccines is expected to augment the market growth over the forecast period. For instance, according
to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million
flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations,
representing 6.5% lowering of disease burden. Moreover, according to a study from the Society for
Risk Analysis, 2016, GDP loss of a pandemic outbreak in the U.S. was recorded between US$ 34.4
billion and US$ 45.3 billion. However, a large population not being vaccinated poses as a restraint for
growth of the market.
Among region, the market in North America held a dominant position in the global adult vaccines
market in 2016. This is attributed to increasing investments facilitated by government as well as the
manufacturers consistently focusing on promoting immunization in the U.S. For instance, in 2015, The
Centers for Medicare & Medicaid Services (CMS), in alignment with the Centers for Disease Control
and Prevention (CDC) introduced a five-year initiative named Healthy People 2020, to improve adult
immunization as well as reduce the disparity rates caused majorly due to pneumonia, shingles, and
influenza by working directly with physicians and provider offices, as well as with home health
agencies, hospitals, beneficiaries and others under the guidance of Health Service Advisory Group
(HSAG). Moreover, favorable Medicare coverage for adult vaccination in the U.S. also poses as a key
factor favoring growth of the adult vaccines market.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1091
Key players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co.,
Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune,
and AstraZeneca Plc.
Market players are engaged in development vaccines to cater to diseases with high epidemic
Market players are increasingly focusing on developing vaccines that caters to diseases with highest
probability of causing an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in
collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country.
The disease affects chronically over 40 million people in the country, as per India’s Universal
Immunization Programme. Moreover, Dynavax Technologies Corporation received FDA approval in
2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran303   documents Email
Document
Category
Health and Medicine
Views
15
File Size
376 KB
Tags
vaccines
1/--pages
Report inappropriate content